Alligator Bioscience Signs Agreement To Sell Mitazalimab to Biossil
(PR-inside.com) LUND, SE / ACCESS Newswire / October 31, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody program HLX22, today announced that it has signed an agreement to sell all rights and assets rela…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


